News Releases

NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Francisco on Wednesday

SHELTON, Conn., Jan. 12, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing anti-viral drugs, reported that its CEO, Eugene Seymour, MD, MPH, will be speaking at the Biotech Showcase conference in San Francisco at 9 am PST Wednesday January 13, 2016. The Biotech Showcase conference is being held at the Parc 55 Hotel in San Francisco, California, from January 11 to January 13th, 2016.

His talk, along with his slides, will be webcast. The link to the webcast is

Dr Seymour will discuss the progress the Company has made since the prior Biotech Showcase conference held a year ago. He will discuss the Company's strategic focus on the HerpeCide™ program, including drug development for herpes keratitis, a potentially blinding disease of the eye. The Company believes that it has achieved the production scale necessary to supply sufficient quantities of an anti-herpes drug candidate for all of the IND enabling studies as well as forthcoming human clinical trials after filing an IND. 

NanoViricides's management will host one-on-one meetings with conference attendees at Biotech Showcase 2016. These meetings have been scheduled through the conference's partnering360 system.

About NanoViricides:
NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

SOURCE NanoViricides, Inc.

For further information: NanoViricides, Inc., Anil R. Diwan,